Stevanato Group (NYSE:STVN) Releases Earnings Results, Misses Expectations By $0.03 EPS

Stevanato Group (NYSE:STVN) posted its quarterly earnings data on Wednesday. The company reported €0.17 EPS for the quarter, missing the consensus estimate of €0.20 by (€0.03), Briefing.com reports. Stevanato Group had a return on equity of 10.52% and a net margin of 11.99%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.18 earnings per share. Stevanato Group updated its FY 2026 guidance to 0.690-0.730 EPS.

Here are the key takeaways from Stevanato Group’s conference call:

• Company reported fiscal 2025 revenue growth of +9% at constant currency (7% reported), led by double‑digit growth in Biopharmaceutical & Diagnostic Solutions and a 29% increase in High‑Value Solutions, which drove ~160 bps of gross‑margin expansion; GLP‑1 sales represented ~19–20% of revenue and grew >50% year‑over‑year.
• For 2026 management guided revenue of €1.26–1.29B (€1.278–1.308B at constant currency), adjusted EBITDA €331.8–346.9M, adj. diluted EPS $0.59–0.63, and assumes an ~€80M FX headwind, gross CapEx €270–290M (net €240–260M) and breakeven to ~€20M free cash flow.
• Capacity expansions in Latina (syringes, upcoming cartridge lines) and Fishers (U.S.) are progressing—Fishers doubled validated customers and has device commercial activity targeted for late 2026/early 2027—expected to support future growth and margin improvement despite near‑term dilution.
• The engineering segment remains a headwind—Q4 revenue fell 23% and 2026 is expected to decline mid‑single to low‑double digits as lower order intake and longer sales cycles delay conversion of the pipeline despite operational optimization and higher site acceptance rates.

Stevanato Group Price Performance

Shares of STVN stock traded up €1.27 during mid-day trading on Wednesday, hitting €16.00. The company had a trading volume of 187,475 shares, compared to its average volume of 723,621. The company has a market capitalization of $4.85 billion, a P/E ratio of 27.95, a P/E/G ratio of 1.21 and a beta of 0.57. The stock’s 50 day moving average price is €17.86 and its 200-day moving average price is €21.78. Stevanato Group has a 52-week low of €13.91 and a 52-week high of €28.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.89 and a quick ratio of 1.30.

Analyst Upgrades and Downgrades

STVN has been the topic of several recent research reports. Wall Street Zen downgraded Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Jefferies Financial Group set a $17.50 target price on shares of Stevanato Group in a research note on Tuesday, February 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stevanato Group in a research report on Monday, December 29th. Finally, Morgan Stanley started coverage on shares of Stevanato Group in a research report on Monday, December 1st. They set an “equal weight” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming lifted its position in Stevanato Group by 39,216.7% during the second quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after purchasing an additional 2,353 shares during the last quarter. GW&K Investment Management LLC raised its position in shares of Stevanato Group by 76.2% during the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock valued at $49,000 after buying an additional 1,055 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Stevanato Group during the 3rd quarter valued at about $68,000. Tower Research Capital LLC TRC lifted its holdings in shares of Stevanato Group by 1,268.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock valued at $112,000 after acquiring an additional 4,250 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Stevanato Group in the third quarter worth about $247,000.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.